Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Careseng 1370 in Healthy Volunteers
NCT03974516Phase 1Terminated
- Sponsor
- i Cure Biotech Co., Ltd.
- Start
- Aug 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of careseng in myelosuppression (4 arms), sponsored by i Cure Biotech Co., Ltd. Primary endpoint: Number of Participants With Adverse Events (AEs) and/or Serious Adverse Events (SAEs). Started Aug 2020; status: terminated.
02
Drugs
careseng
03
Conditions
myelosuppression
Beyond the preview
Go deeper on NCT03974516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03974516.